<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03765671</url>
  </required_header>
  <id_info>
    <org_study_id>GFT505-118-14</org_study_id>
    <nct_id>NCT03765671</nct_id>
  </id_info>
  <brief_title>Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients</brief_title>
  <official_title>An Open-label, Phase 1, Single-dose Study to Evaluate the Pharmacokinetics of Elafibranor 120 mg in Adult Subjects With Hepatic Impairment and Adult Healthy Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genfit</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genfit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted in order to assess the need for dose adjustment for elafibranor&#xD;
      in patients with hepatic impairment. Pharmacokinetic parameters of elafibranor and its active&#xD;
      metabolite (GFT1007) will be compared in hepatic impaired patients (mild, moderate and severe&#xD;
      according to Child-Pugh categories) versus healthy participants after a single oral&#xD;
      administration of elafibranor 120 mg.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Actual">June 14, 2019</completion_date>
  <primary_completion_date type="Actual">June 7, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve from dosing time to last measurement (AUC(0-t)) of elafibranor and active metabolite</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired patients</time_frame>
    <description>In participants with mild, moderate and severe hepatic impairment compared to healthy volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under curve from dosing time to infinity (AUC(0-∞)) of elafibranor and active metabolite</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired patients</time_frame>
    <description>In participants with mild, moderate and severe hepatic impairment compared to healthy volunteers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: maximum plasma drug concentration (Cmax)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants</time_frame>
    <description>for elafibranor and metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: elimination half-life (t1/2)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants</time_frame>
    <description>for elafibranor and metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: apparent volume of distribution (Vd/F)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants</time_frame>
    <description>for elafibranor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: renal clearance (CLr)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants</time_frame>
    <description>for elafibranor and metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: apparent non renal clearance (CLnr/F)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants</time_frame>
    <description>for elafibranor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: apparent total clearance (CL/F)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants</time_frame>
    <description>for elafibranor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total area under the plasma concentration-time curve (%AUCextra)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants</time_frame>
    <description>for elafibranor and metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: area under curve from dosing time to last measurement (AUC(0-t)) of glucuronide metabolites and corresponding aglycones</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants</time_frame>
    <description>for the glucuronide metabolites of elafibranor and corresponding aglycones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: area under curve from dosing time to infinity (AUC(0-∞)) of glucuronide metabolites and corresponding aglycones</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired patients</time_frame>
    <description>for the glucuronide metabolites of elafibranor and corresponding aglycones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics: amount excreted (Ae)</measure>
    <time_frame>pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics: cumulative amount excreted (Ae0-t)</measure>
    <time_frame>pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics: percentage of dose excreted (Fe)</measure>
    <time_frame>pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics: cumulative percent of dose excreted (Fe0-t)</measure>
    <time_frame>pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics: renal clearance (CLR)</measure>
    <time_frame>pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hepatic Impairment</condition>
  <condition>Liver Disease</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Mild Child-Pugh A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of elafibranor 120mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Child-Pugh B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of elafibranor 120mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Child-Pugh C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of elafibranor 120mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of elafibranor 120mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elafibranor</intervention_name>
    <description>120mg oral single dose</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Mild Child-Pugh A</arm_group_label>
    <arm_group_label>Moderate Child-Pugh B</arm_group_label>
    <arm_group_label>Severe Child-Pugh C</arm_group_label>
    <other_name>GFT505</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - For all participants:&#xD;
&#xD;
          1. Males or females, between 18 and 75 years of age, inclusive;&#xD;
&#xD;
          2. With a minimum body weight of 50 kg and within a BMI range of 18.0 to 40.0 kg/m²,&#xD;
             inclusive;&#xD;
&#xD;
          3. Females participating in this study must be of non-childbearing potential or using&#xD;
             highly efficient contraception for the full duration of the study&#xD;
&#xD;
          4. Negative serum pregnancy test at screening (if applicable);&#xD;
&#xD;
          5. Negative human immunodeficiency virus antibody screens at Screening;&#xD;
&#xD;
               -  For hepatically impaired participants:&#xD;
&#xD;
          6. Participants who have chronic (≥ 6 months) mild, moderate, or severe hepatic&#xD;
             insufficiency (of any etiology) that has been clinically stable (no acute episodes of&#xD;
             illness due to deterioration in hepatic function) for at least 1 month prior to&#xD;
             Screening Currently on a stable medication regimen&#xD;
&#xD;
               -  For healthy volunteers with normal hepatic function:&#xD;
&#xD;
          7. Non-smokers&#xD;
&#xD;
          8. Matched to participants with Mild and/or Moderate and/or Severe hepatic impairment in&#xD;
             age (± 10 years), BMI (± 20 percent) and gender.&#xD;
&#xD;
        Other protocol-defined inclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - For all participants:&#xD;
&#xD;
          1. A positive alcohol test result at Check-in;&#xD;
&#xD;
          2. A history of alcohol abuse in the prior 2 years;&#xD;
&#xD;
          3. Positive urine screen for drugs of abuse at Screening or Check-in.&#xD;
&#xD;
          4. Strenuous exercise within 72 hours prior to Check-in;&#xD;
&#xD;
          5. Blood donation or loss of blood (excluding volume drawn at screening or menses) of 50&#xD;
             mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the&#xD;
             dosing;&#xD;
&#xD;
          6. History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs except that appendectomy and&#xD;
             hernia repair will be allowed. Bariatric surgery will not be allowed.&#xD;
&#xD;
          7. Presence or history of malignancy within the prior 3 years, with the exception of&#xD;
             treated basal cell or squamous cell carcinoma;&#xD;
&#xD;
          8. Poor peripheral venous access;&#xD;
&#xD;
          9. Receipt of blood products within 2 months prior to Check-in;&#xD;
&#xD;
               -  For hepatically impaired participants:&#xD;
&#xD;
         10. History of unstable diabetes mellitus Subjects who have a transjugular intrahepatic&#xD;
             portosystemic shunt and/or have undergone portacaval shunting;&#xD;
&#xD;
         11. Participant has shown evidence of hepatorenal syndrome or has creatinine clearance ≤&#xD;
             60 mL/min Subject has required treatment for GI bleeding within the 6 months prior to&#xD;
             Check in;&#xD;
&#xD;
         12. Recent history of paracentesis (&lt; 3 months prior to Check-in);&#xD;
&#xD;
         13. Participants with Wilson's disease, alpha-1 antitrypsin deficiency, glycogen storage&#xD;
             diseases, or galactosemia;&#xD;
&#xD;
         14. Participants with anemia secondary to hepatic disease, unless hemoglobin is ≥ 9 g/dL&#xD;
             and anemia symptoms are not clinically significant. Subjects must have ≥ 35 000&#xD;
             platelets at screening and at Day -1;&#xD;
&#xD;
               -  For healthy volunteers with normal hepatic function:&#xD;
&#xD;
         15. Significant history or clinical manifestation of any metabolic (including thyroid),&#xD;
             allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular&#xD;
             (including any prior history of cardiomyopathy or cardiac failure), gastrointestinal&#xD;
             (GI), neurological, or psychiatric disorder;&#xD;
&#xD;
         16. Positive serologic test for hepatitis B surface antigen or for hepatitis C virus&#xD;
             antibody at Screening;&#xD;
&#xD;
         17. Frequent headaches (&gt; twice a month) and/or migraines, recurrent nausea and/or&#xD;
             vomiting;&#xD;
&#xD;
         18. Participants with symptomatic hypotension at Screening, whatever the decrease of blood&#xD;
             pressure, or asymptomatic postural hypotension;&#xD;
&#xD;
         19. Cholecystectomy&#xD;
&#xD;
        Other protocol-defined exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal BIRMAN, MD</last_name>
    <role>Study Director</role>
    <affiliation>Genfit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Clinical Pharmacology, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>inVentiv Health Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

